Literature DB >> 26390818

A new predictor of mortality in hemodialysis patients; Tenascin-C.

Sukru Ulusoy1, Gulsum Ozkan2, Ahmet Menteşe3, Beyhan Guvercin4, S Caner Karahan3, Adnan Yavuz5, Diler Us Altay3.   

Abstract

AIM: Cardiovascular disease is the most frequent cause of mortality in hemodialysis patients. There are a number of inconsistencies in terms of cardiovascular risk factors in these patients. Tenascin C (TN-C) is a matricellular protein which may be a prognostic predictor after myocardial infarction and many cardiac diseases. The purpose of this study was to determine TN-C levels in hemodialysis patients and to evaluate the association between TN-C levels and cardiac mortality. MAIN
METHODS: In this multicenter prospective observational research, blood specimens were collected at the start of the study for the measurement of TN-C and other biochemical parameters. After 2 years' follow-up we investigated the association between TN-C and other biochemical and demographic parameters and cardiac and all cause mortality. KEY
FINDINGS: Two hundred thirty-eight patients and 25 healthy individuals were enrolled. TN-C levels in the hemodialysis group were higher than those in the control group (p b 0.001). All-cause mortality was observed in 47 (19%) patients and cardiac mortality in 39 (15%). At multivariate Cox regression analysis, TN-C, age and systolic blood pressure were identified as independent predictors of cardiac mortality. The Kaplan–Meier survival curve revealed greater all-cause and cardiac mortality rates in the high TN-C group (Log rank p b 0.001 and p b 0.05 respectively). SIGNIFICANCE: TN-C levels were higher than those in the control group, and our results suggest that it may be a predictor of cardiac mortality in hemodialysis patients. If further studies support our research, TN-C may be a useful biomarker for detecting cardiac mortality risk.

Entities:  

Keywords:  Cardiac mortality; Hemodialysis; Mortality; Tenascin C

Mesh:

Substances:

Year:  2015        PMID: 26390818     DOI: 10.1016/j.lfs.2015.09.011

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Serum tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a French prospective cohort.

Authors:  Barnabas Gellen; Nathalie Thorin-Trescases; Eric Thorin; Elise Gand; Philippe Sosner; Sonia Brishoual; Vincent Rigalleau; David Montaigne; Vincent Javaugue; Yann Pucheu; Philippe Gatault; Xavier Piguel; Samy Hadjadj; Pierre-Jean Saulnier
Journal:  Diabetologia       Date:  2020-02-10       Impact factor: 10.122

2.  Elevated Serum Tenascin-C Predicts Mortality in Critically Ill Patients With Multiple Organ Dysfunction.

Authors:  Yunyu Xu; Nanyang Li; Jiamin Gao; Da Shang; Min Zhang; Xiaoyi Mao; Ruiying Chen; Jianming Zheng; Ying Shan; Mingquan Chen; Qionghong Xie; Chuan-Ming Hao
Journal:  Front Med (Lausanne)       Date:  2021-11-26

Review 3.  The Role of Matrix Proteins in Cardiac Pathology.

Authors:  Katie Trinh; Sohel M Julovi; Natasha M Rogers
Journal:  Int J Mol Sci       Date:  2022-01-25       Impact factor: 5.923

4.  Midkine release during hemodialysis is predictive of hypervolemia and associates with excess (cardiovascular) mortality in patients with end-stage renal disease: a prospective study.

Authors:  Sabine Brandt; Anja Fischer; Carla Kreutze; Dorothea Hempel; Xenia Gorny; Florian G Scurt; Delia L Şalaru; Peter Bartsch; Anja Bernhardt; Stefanie M Bode-Böger; Matthias Girndt; Roman Fiedler; Berend Isermann; Jonathan A Lindquist; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2022-02-24       Impact factor: 2.266

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.